Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.
about
Better quality of life with neuropsychological improvement on HAART.A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART.Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management.Development of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV.Chronicity and remission of fatigue in patients with established HIV infection.Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive statusGender differences in factors associated with adherence to antiretroviral therapy.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsModafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.Physiological and psychosocial factors that predict HIV-related fatiguePsychometric properties of a Symptom Management Self-Efficacy Scale for women living with HIV/AIDS.Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients.Patient and provider-reported symptoms in the post-cART era.Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi.Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trialSimplified regimens for treating HIV infection and AIDS.A closer look at depression and its relationship to HIV antiretroviral adherence.Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.Disability and Living with HIV: Baseline from a Cohort of People on Long Term ART in South Africa.Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and ZambiaPharmacologic perspectives for once-daily antiretroviral therapy.HIV or HIV-therapy? Causal attributions of symptoms and their impact on treatment decisions among women and men with HIV.Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovirSelf-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective StudyAdherence to Antiretroviral Therapy (ART) in Yaoundé-Cameroon: Association with Opportunistic Infections, Depression, ART Regimen and Side Effects.Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients.Demographic and illness-related variables associated with HIV-related fatigue.Psychosocial factors in adherence to antiretroviral therapy among HIV-positive people who use drugs.The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysisTreatment Buddies Improve Clinic Attendance among Women but Not Men on Antiretroviral Therapy in the Nyanza Region of Kenya.Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy.HIV prevention: What have we learned from community experiences in concentrated epidemics?Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale.Trauma, stressful life events and depression predict HIV-related fatigue.Factors associated with HIV viral load in a respondent driven sample in Los AngelesMitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy statusLiving with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional studyDifficulties reported by HIV-infected patients using antiretroviral therapy in Brazil.
P2860
Q25256813-51A69FE0-D255-4EF2-9493-40E6D34A697DQ30230364-F0741455-E19A-4C0E-8838-31482D589D2EQ30353427-EDDDBEBE-622D-4A48-9811-137403BC7B37Q33477968-58F02F8E-D8E9-48C3-B370-8E467ABFDA8AQ33797588-09C2948A-1807-446B-A9DD-9DA5B0DFD4DBQ33827543-710422B0-DD56-4AB3-B09C-98A83FED339EQ33938482-DC47FDF4-5CFD-428B-8AC7-0406E9485B49Q33939069-63CEF0F6-520A-48F1-B1A9-2BB37001AEC5Q33940587-8E990F7E-7951-4E7E-80DA-F88C78FBCD28Q34288374-6D3F358E-FAB5-41A0-819A-3A8DA03B527EQ34709059-C755B808-6F19-4E95-BE8E-D863A9F8D35FQ35016337-BDB82CE4-5DDF-490E-AF95-A40B870C0B51Q35055102-42EB3AC6-951E-45D4-AEB2-B014940DC669Q35056675-910C4C72-D861-4D2A-A7DE-056E0AC20777Q35098738-B62128AF-403E-40F5-B8F9-871B45075940Q35124367-409558DD-0805-440C-B582-79A8F0094AE1Q35203402-1D9A8973-3D21-4DE3-91DB-52C40DD99E11Q35580641-29EBB83B-5B9F-423B-87F1-749064CD5B62Q35588145-8C40514A-BC65-433F-8D17-6AF7CF2367E1Q35820243-5C1992F2-444B-4BCC-8446-877A4F6D923CQ35857129-BC26FE2D-2F7F-4ECD-B8ED-2255BBF5DFB7Q35898792-6D9ABA3E-8BA7-4726-8461-B365809E99C1Q35915916-398F870F-53E2-4A58-822F-E26B53623C38Q36105896-618998D4-E89C-4C3F-962A-C17D9C8C8818Q36142875-BF881F57-C4CA-4C40-B2A1-F4E7E773D790Q36167659-A6BB8621-982D-4F0F-80D8-4C4750F3E1EFQ36265139-8C82133E-041B-46CC-87D0-51A9328C78B3Q36376395-2EF1F675-FB9D-4D15-828E-D3D5CC883E24Q36527348-C9F01A35-8DB7-4451-960E-F3E838DE428DQ36599164-73F4AD83-91EB-4CC1-B375-F50508CC2DF2Q36733621-772A6EEA-BBF1-4FAE-BFC9-1C82D4E0583FQ36764611-30723934-2902-43C7-BB67-9248C6DEFD7FQ36844848-CEE6847F-7FCC-4AB7-87BA-3367A22C4671Q36975277-EE9419F2-BBA5-4D9B-84BA-4F45144988ACQ36981888-874CE749-013A-42FA-A8F0-09BBB7A0D920Q37015939-78FF8DE2-9599-4CC8-908E-590D10B54DFEQ37113436-B7E17239-A91F-4808-BF58-B9102B8AA272Q37114196-2F5DDD09-676A-48FF-A0B9-D28AC61C8864Q37120527-1C139CA6-DA63-4124-9FD0-801EE5C62B08Q37147351-156B8D62-0B7F-4F6F-9DE7-B01333E7CCCE
P2860
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Self-reported symptoms after i ...... impact on adherence to HAART.
@en
type
label
Self-reported symptoms after i ...... impact on adherence to HAART.
@en
prefLabel
Self-reported symptoms after i ...... impact on adherence to HAART.
@en
P2093
P2860
P1433
P1476
Self-reported symptoms after i ...... impact on adherence to HAART.
@en
P2093
APROCO Cohort Study Group
J P Moatti
V Cailleton
P2860
P356
10.1310/R8M7-EQ0M-CNPW-39FC
P50
P577
2001-01-01T00:00:00Z